Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 Synthesis 2 References

Mibefradil

●Cymraeg ●Español ●فارسی ●Français ●Polski ●Русский ●Српски / srpski ●Srpskohrvatski / српскохрватски ●Suomi Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version In other projects ●Wikimedia Commons Appearance From Wikipedia, the free encyclopedia

Mibefradil
Clinical data

Trade names	Posicor
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a607007
Routes of administration	By mouth (tablets)
ATC code	C08CX01 (WHO)
Legal status
Legal status	Withdrawn from market
Pharmacokinetic data
Bioavailability	70%
Protein binding	>99%
Metabolism	Liver (CYP3A4)
Elimination half-life	17–25 hours
Identifiers
IUPAC name (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
CAS Number	116644-53-2^Y
PubChem CID	60662
IUPHAR/BPS	2522
DrugBank	DB01388^N
ChemSpider	54673^N
UNII	27B90X776A
KEGG	D08217^Y
ChEMBL	ChEMBL45816^N
PDB ligand	MWV (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID1023318
Chemical and physical data
Formula	C₂₉H₃₈FN₃O₃
Molar mass	495.639 g·mol⁻¹
3D model (JSmol)	Interactive image
Melting point	128 °C (262 °F) (dihydrochloride salt)
SMILES CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
InChI InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1^N Key:HBNPJJILLOYFJU-VMPREFPWSA-N^N
^NY (what is this?) (verify)

Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.^[1]

The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels,^[1] which is probably responsible for many of its unique properties.^{[citation needed]}

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.^[2]